Prior to the approval of immune checkpoint blockade in the first-line setting with PD-1/PD-L1 and CTLA-4 antibodies, four cycles of platinum doublet chemotherapy was a standard approach to the treatment of patients with metastatic NSCLC. Here, CTLA4 is linked to non-small cell lung carcinoma.